{"public_id":"cl_c9dd1ea4d9210cb4d05b482e138ada3f","status":"active","superseded_by_public_id":null,"corpus_id":6351267,"text":"Adverse event rates did not differ across treatment groups, and adjudicated cardiovascular event rates were similarly low.","confidence":0.93,"paper":{"corpus_id":6351267,"title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","url":"https://sah.borca.ai/papers/6351267"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.93,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_3590f1454616800c44d6ecf04a210910","name":"treatment groups","description":"The randomized study arms compared in the trial.","types":["study arm"],"url":"https://sah.borca.ai/concepts/co_3590f1454616800c44d6ecf04a210910"},{"public_id":"co_440ed2c37c5219fe7fd33cd9dabd6945","name":"adverse events","description":"Unwanted medical events monitored to assess treatment safety.","types":["safety outcome"],"url":"https://sah.borca.ai/concepts/co_440ed2c37c5219fe7fd33cd9dabd6945"},{"public_id":"co_b4c7d87f2675e804735f74e2795a33e3","name":"adjudicated cardiovascular event rates","description":"Blinded, adjudicated rates of cardiovascular adverse events and death used in safety assessment.","types":["safety outcome"],"url":"https://sah.borca.ai/concepts/co_b4c7d87f2675e804735f74e2795a33e3"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_c9dd1ea4d9210cb4d05b482e138ada3f"}